SPINK5, encoding the putative multi-domain serine protease inhibitor LEKTI, was recently identified as the defective gene in the severe autosomal recessive ichthyosiform skin condition, Netherton Syndrome (NS). Using monoclonal and polyclonal antibodies, we show that LEKTI is a marker of epithelial differentiation, strongly expressed in the granular and uppermost spinous layers of the epidermis, and in differentiated layers of stratified epithelia. LEKTI expression was also demonstrated in normal differentiated human primary keratinocytes (HK) through detection of a 145 kDa full-length protein and a shorter isoform of 125 kDa. Both proteins are N-glycosylated and rapidly processed in a post-endoplasmic reticulum compartment into at least 3 C-terminal fragments of 42, 65 and 68 kDa, also identified in conditioned media. Processing of the 145 and 125 kDa precursors was prevented in HK by treatment with a furin inhibitor. In addition, in vitro cleavage of the recombinant 145 kDa precursor by furin generated C-terminal fragments of 65 and 68 kDa, further supporting the involvement of furin in LEKTI processing. In contrast, LEKTI precursors and proteolytic fragments were not detected in differentiated HK from NS patients. Defective expression of LEKTI in skin sections was a constant feature in NS patients, whilst an extended reactivity pattern was observed in samples from other keratinizing disorders, demonstrating that loss of LEKTI expression in the epidermis is a diagnostic feature of NS. The identification of novel processed forms of LEKTI provides the basis for future functional and structural studies of fragments with physiological relevance.
INTRODUCTION

4
D15 perfectly match the typical Kazal motif (C -(X) n -C-(X) 7 -C-(X) 10 -C-(X) 2/3 -C-(X) m -C), whilst other domains exhibit a Kazal-type-derived four-cysteine residue pattern. The isolation of individual domains D1, D5 and D6 from human hemofiltrate (14, 15) revealed that LEKTI fulllength protein most likely represents an inactive precursor, the proteolytic processing of which would be required for the release of bioactive forms. A 30 kDa polypeptide with an N-terminal sequence matching D8 of LEKTI was also purified from HK conditioned medium (16) .
Subtilisin -like proprotein convertases (SPC) are a family of endoproteases responsible for the processing of numerous inactive prohormones and other proproteins into their biologically active forms (17) . SPCs display a specific tissue distribution and cellular localisation (17) , and cleave their substrates at the general motif (K/R)-Xn-(K/R) ↓ (n= 0, 2, 4 or 6; X: any amino acid) (18) . A number of these consensus sequences have been identified within the amino -acid sequence of LEKTI, suggesting that SPCs may be involved in the proteolytic processing of LEKTI (13) .
Analysis of the human tissue distribution of SPINK5 transcripts predicts high expression levels of LEKTI in thymus, vaginal epithelium, oral mucosa, tonsils, and Bartholin's and parathyroid glands (14) . More recently, in situ hybridization has revealed the localisation of SPINK5 transcripts to the uppermost spinous layers and the granular layer of normal human epidermis (13) . The authors also reported a marked increase in trypsin -like hydrolytic activity in the cornified layer of NS patients. This finding, together with the demonstration of a trypsininhibiting activity for D5 and D6 domains (14, 15) , supports a key role for LEKTI in the regulation of proteolytic events involved in skin barrier formation and maintenance.
To further characterise LEKTI human tissue distribution and investigate protein expression in HK from normal controls and NS patients, we developed monoclonal and polyclonal anti-N, and polyclonal anti-C terminal, antibodies. We report the first detection of the full-length protein, together with the identification of a shorter isoform in normal HK. We 5 show that both precursors are N-glycosylated and rapidly cleaved in a post-endoplasmic reticulum compartment to generate at least three C-terminal fragments, and provide evidence that furin is involved in LEKTI processing. We also describe the protein expression in normal stratified epithelia, and demonstrate that loss of LEKTI expression in the epidermis is a diagnostic feature of NS.
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RESULTS
Characterisation of LEKTI expression in normal HK
Given the predicted expression of LEKTI in the uppermost differentiated layers of the epidermis, we assessed the immunospecificity of the newly generated antibodies on proliferating and differentiated cultured HK. Terminal differentiation was induced by switching the ionic calcium content of the culture medium from low (<0.1 mM) to high (1.2 mM) concentrations, as previously described (19, 20) .
Immunolocalisation of LEKTI-HK were cultured for 24 hours in low or high calcium conditions and analysed by immunofluorescence microscopy using antibodies generated against the C-terminus of LEKTI (α-C). A strong labelling was observed in differentiated cells ( Fig.1B; green) whilst only very low protein levels were present in cells grown in proliferating conditions (Fig. 1A) . No labelling was observed using pre-immune serum (data not shown). The specificity of labelling was subsequently confirmed by antigen competition experiment.
Incubation of antibodies with recombinant antigen, prior to immunodetection, led to a dramatic reduction in signal intensity (Fig. 1C ). Since the labelling showed an extensive reticular pattern characteristic of the endoplasmic reticulum (ER), we performed double staining using α-C antibodies ( Fig.1D ) and an antibody specific for the ER marker protein, calreticulin (Fig. 1E ).
Superimposition showed significant overlap (Fig. 1F) , indicating that the majority of LEKTI is localised in the ER. Similar results were obtained using antibodies generated against the Nterminus of LEKTI (α-N; data not shown).
Molecular detection of LEKTI-HK were cultured as above, and analysed by western blot using α-C antibodies ( Fig. 2A) . Three bands of approximately 42, 65 and 68 kDa were detected in total cell extract (lane 2) and conditioned medium (lane 3) from differentiated cells, but not in undifferentiated cells (lane 1). These signals were not detected using pre-immune serum (Fig. 7 2B; lane 1) or α-N antibodies (data not shown). As above, we confirmed the signal specificity by antigen competition experiment ( Fig. 2B; lanes 2 and 3) . We also examined a lower protein molecular weight range, but no additional N-or C-terminal specific fragments were identified by the corresponding antibodies (data not shown).
The molecular weight of LEKTI predicted by the amino acid sequence is 118 kDa.
Although both α-N and α-C antibodies detected LEKTI in the ER of differentiated HK, only 42, 65 and 68 kDa proteins were identified in the corresponding cell extracts by α-C antibodies.
These data suggest that LEKTI is rapidly processed in a post-ER compartment and that the 42, 65 and 68 kDa proteins represent C-terminal proteolytic forms. In an attempt to detect the fulllength protein, we treated differentiated HK with brefeldin A (BFA), a drug that blocks ER to Golgi protein transport (21) . Western blot analysis of these cell extracts (Fig. 2C ) revealed two high molecular w eight bands of approximately 125 and 145 kDa using α-C (lane 2) and α-N (lane 4) polyclonal antibodies, that were not detected in the absence of BFA (lanes 1 and 3, respectively). Note that only very low levels of the three C-terminal fragments were detected under such conditions (lane 2). In contrast, pre -immune sera failed to recognise the 125 or 145 kDa proteins ( Fig. 2D ; lane 1, α-C and lane 4, α-N). The specificity of these bands was further confirmed by antigen competition experiments ( Fig. 2D ; lanes 2 and 3, α-C and lanes 5 and 6, α-N), indicating that both the 125 and 145 kDa proteins were derived from LEKTI.
LEKTI is expressed as two N-glycosylated precursor isoforms in HK
We previously detected the expression of a single 3.7 kb SPINK5 transcript in cultured HK (10, 12) , whose size is consistent with the full-length protein (14) . Since BFA treatment revealed two specific signals, we tested whether the 145 kDa band could correspond to the glycosylated form of the 125 kDa protein, which approximately matches LEKTI predicted size. Total cell extracts from differentiated HK treated with BFA were incubated in the presence or absence of at Pennsylvania State University on http://hmg.oxfordjournals.org/ Downloaded from the peptide N-glycosidase F (PGNaseF) and analysed by western blot using α-C antibodies.
PGNase F treatment resulted in a molecular weight shift of approximately 10 kDa for both proteins ( Fig. 3; compare lanes 1 and 2) . These results indicate that the 125 and 145 kDa bands correspond to N-glycosylated forms of two separate precursors of LEKTI, with apparent molecular weights of approximately 115 and 135 kDa, respectively.
To confirm the identity of the 145 kDa band as the N-glycosylated form of LEKTI fulllength precursor, COS-1 cells were transfected with full-length LEKTI cDNA. Western blot analysis using α-N (data not shown) or α-C (Fig. 3) 
Furin is involved in the processing of LEKTI in HK
The absence of cleavage of the recombinant full-length protein in COS-1 cells prompted us to test furin, a subtilisin-like proprotein convertase expressed in the epidermis (22) , as a potential candidate for the endoproteolytic processing of LEKTI.
Protein extracts from COS-1 cells overexpressing LEKTI were incubated with human recombinant furin for increasing times, and analysed by western blot using α-C antibodies (Fig.   4A ). Interestingly, the appearance of 65 and 68 kDa fragments were first detected 7 minutes after furin addition (lane 3), and were not observed in total cell extracts (lane 1), or after a short after 60 minutes (lane 7). The 65 and 68 kDa proteolytic products generated from incubation of over-expressed LEKTI with furin in these experiments migrated at the same size as two of the C-terminal proteolytic forms identified in HK (Fig. 2) .
To confirm the involvement of furin in the physiological processing of LEKTI, differentiated HK were cultured for 6 hours with increasing concentrations of the furin inhibitor, Dec-RVKR-CMK, or in the presence of brefeldin A (BFA) as a control (Fig. 4B) .
Consistent with our previous results ( Significantly, incubation with the furin inhibitor (lanes 2 and 3) had a similar effect to that of BFA: there was a strong inhibition of processing of the native 125 and 145 kDa precursors into the 42, 65 and 68 kDa proteolytic forms. These results further implicate furin in the processing of LEKTI precursors into the three C -terminal proteolytic forms identified in HK extracts.
LEKTI expression is impaired in HK from NS patients
We investigated LEKTI expression in HK from three NS patients, termed NS1, NS2 and NS3, whose SPINK5 mutations introduce premature termination codons of translation ( (12); patients 10, 11 and 12, respectively).
We first compared the relative expression levels of SPINK5 transcript in normal (N) and NS patient (NS1-3) differentiated HK by northern blot analysis. A dramatic reduction of the 3.7 kb signal was observed for all three patients compared to control (Fig. 5A) , suggesting nonsense-mediated mRNA decay and predicting severe impairment of LEKTI expression.
LEKTI protein levels were subsequently examined by western blot analysis of cell extracts from normal (N) and NS (NS1-3) differentiated HK treated in the presence (Fig. 5B) or absence ( Fig. 5C ) of BFA. Importantly, the full-length protein was only detected in normal controls incubated with BFA, and not in NS patient cell extracts (Fig. 5B) . Similarly, the 42, 65 and 68kDa proteolytic fragments were not observed in NS samples, but were present in the control (Fig. 5C ). These data confirm that the 145 and 125 kDa full length proteins, and the 68, 65 and 42 kDa fragments, are encoded by SPINK5, and provide the first conclusive evidence for defective expression of LEKTI in NS.
LEKTI expression in normal tissues
Paraffin wax-embedded sections of a variety of normal human tissues were tested for reactivity with LEKTI antibodies by immunohistochemistry. α-C polyclonal, and α-N monoclonal and polyclonal antibodies showed similar labelling patterns throughout the tissues investigated (Table 1) . A strong immunoreactivity was detected in interfollicular epidermis of the skin and was localised to the cytoplasm of keratinocytes of the granular and uppermost spinous layers; the horny layer was negative. In the granular layer, the labelling often appeared more intense at the cell periphery and in the upper cytoplasm, forming a cuff above the nucleus and resulting in a polarised appearance (Fig. 6A ). Antigen competition completely abolished the labelling, confirming its specificity (Fig. 6B) . Staining was also observed in cells lining acrosyringeal ducts of hair follicles ( Fig. 7A-C) , and in the duct of sebaceous glands (Fig. 7D) . In hair follicles, the labelling of the hair bulb was restricted to matrical cells that differentiate into the inner root sheath and hair shaft ( Fig. 7A-4 and 7C). Upper to the hair bulb, the inner root sheath layers and hair cuticle were stained, whilst the outer root sheath was negative ( Fig. 7B-3 and   7C ). In the hair isthmus, reactivity was limited to inner cells of the outer root sheath surrounding the hair shaft ( Fig. 7A-2 ). The follicular infundibulum displayed a staining pattern similar to that observed in interfollicular epidermis ( Fig. 7A-1 ). In the thymus, LEKTI was abundantly expressed in Hassall's corpuscles, which represent the terminal differentiation stages of the thymic medullary epithelium (Fig. 7E ). Strong expression was also detected in the gingival mucosa, mainly localised to the upper half of the stratum spinosum (Fig. 7F ). An extended labelling was observed throughout suprabasal layers of the vaginal mucosa ( Fig. 7G) and uterine ectocervix (Fig. 7H ). The tonsillar epithelium (Fig. 7I ) and the oesophagus (data not shown) also showed positive staining. In contrast, no labelling was found in the epithelia of the gastrointestinal tract, liver, lung and kidney (data not shown). No specific staining was detected in the remainder of the organs tested (Table 1 ). In all tissues examined, no labelling was observed using the corresponding pre-immune sera (data not shown). Further confirmation of antibody specificity was provided by antigen competition (data not shown).
LEKTI expression in congenital erythrodermas, keratinizing and inflammatory skin diseases
Skin sections from patients affected with congenital erythrodermas, inherited disorders of keratinization and inflammatory skin diseases were tested for reactivity with LEKTI antibodies (Table 2 ). Immunostaining of skin sections from 21 patients with proven NS showed no detectable protein expression in 20 patients, including NS1, NS2 and NS3 ( 
DISCUSSION
In this study, we report the first cellular and tissue detection of lympho-epithelial Kazal-type related inhibitor (LEKTI) using anti-C and anti-N terminal specific antibodies. We demonstrate that LEKTI is a marker of epithelial differentiation whose expression, like most differentiationspecific proteins (23, 24) , is regulated in cultured keratinocytes by external calcium concentrations. We have shown that LEKTI is expressed in differentiated human primary keratinocytes (HK) as two N-glycosylated precursor proteins of 145 and 125 kDa. However, under the experimental conditions used, these proteins were only detected when ER to Golgi transport was inhibited with brefeldin A, indicating rapid intracellular processing in a post-ER compartment of the secretory pathway. In addition, we identified three C-terminal proteolytic fragments of 42, 65 and 68 kDa in both cell extracts and conditioned medium. Time course analysis over 72 hours of cell differentiation showed no further processing of these proteolytic forms (data not shown). These data suggest that the 42, 65 and 68 kDa polypeptides represent stable, and thereby potentially biologically active, forms of LEKTI. They also indicate that the inhibitory action of LEKTI-derived peptides/polypeptides (14, 15) could target secreted and/or cell-surface-exposed serine proteases. In contrast to HK, no processing of the overexpressed processing of the SPINK5 pre-mRNA in keratinocytes (A.Tartaglia -Polcini et al., manuscript in preparation), suggesting that the 42 kDa fragment could originate from the cleavage of this isoform. We have also shown that treatment of HK with the furin inhibitor, Dec-RVKR-CMK, prevents the processing of both endogenous precursors, further implicating furin in the intracellular processing of LEKTI. This is likely to occur in the trans-Golgi network where the active form of furin resides (25) . Co-localisation of furin and LEKTI in the granular layer of the epidermis (22) further supports this hypothesis. However, expression of other subtilisin -like proprotein convertases (SPC), including PACE4, PC5/PC6, PC7/8 and PC8, have been demonstrated in human epidermis (22, 26) , raising the possibility that these endo-proteases could also be involved in the proteolytic processing of LEKTI.
The number of consensus sequences for SPC cleavage identified within LEKTI could generate at least 14 polypeptides (13). However, identification of the 42, 65 and 68 kDa Cterminally processed forms in this study, together with a 30 kDa polypeptide (16) , reveals that only a selected proportion of these sites are used during the in vivo processing of LEKTI.
Interestingly, processing of the N-terminal half of LEKTI seems to generate single domains (D1, D5, D6) (14, 15) , whilst the C-terminal half produces larger multi-domain fragments.
These fragments may result from selective post-translational proteolysis (27) with a different processing in various tissues depending on the enzymes involved. The reasons we could not detect D1, D5 and D6 in HK using α-N antibodies raised against D1-D6 remain unclear; however, this could be due to the lack of epitope recognition within these domains and/or the rapid degradation of single protein domains under the experimental conditions used.
LEKTI tissue distribution pattern clearly demonstrates a specific expression in the most differentiated viable layers of stratified epithelial tissues (Table 1) . These included keratinizing (skin and its appendages, gingiva and thymus), as well as non-keratinizing (tonsil, esophagus, vagina and uterine ectocervix) epithelia. In the epidermis, LEKTI expression was mainly restricted to the granular layer, where critical biochemical and morphological changes of terminal differentiation lead to cornification (28) . In hair follicle, the strong expression of LEKTI in matrical cells of the bulb, the hair shaft cuticle and inner root sheath, suggest a possible role in hair growth and differentiation. In non-keratinizing epithelia, LEKTI expression was more diffuse throughout the upper half of the spinous layers, supporting a role for the protein in earlier stages of epithelial differentiation.
We have shown that the absence of LEKTI expression in HK and epidermis is a common feature of NS. Although very low levels of LEKTI could be detected in skin sections of one patient, these results demonstrate that loss of LEKTI expression is the major molecular mechanism underlying NS. In contrast, normal or slightly reduced levels of LEKTI were detected in all other inherited and acquired skin diseases examined, including a number of clinically resembling skin disorders (Table 2 ). This finding reveals that defective expression of LEKTI in the epidermis is a diagnostic feature of NS, thus providing the basis for the powerful use of LEKTI antibodies for rapid, early and reliable diagnosis of NS. In a variety of other inherited keratinizing disorders tested, LEKTI expression appears to be upregulated and is extended to several spinous layers. The various epidermal responses mounted to compensate for altered epidermal permeability barrier in these diseases, from cytokine production by keratinocytes to the modulation of epidermal calcium gradient (23, 29, 30) , could be involved in driving increased expression of LEKTI. Interestingly, LEKTI expression pattern in these diseases does not match that of any known epithelial differentiation protein, such as loricrin, involucrin or filaggrin (31, 32) . This indicates that specific mechanisms are involved in the transcriptional/post-transcriptional regulation of LEKTI expression. In psoriasis and neonatal/infantile erythrodermas (due to immune deficiency or atopy), an irregular LEKTI staining pattern is detected. In particular, decreased expression corresponds to the presence of an intense lympho-mononuclear inflammatory infiltrate invading the epidermis, suggesting that some inflammatory cytokines could downregulate LEKTI expression.
Although the biological function(s) of LEKTI is still unknown, its specific expression in highly differentiated regions of lympho-epithelial tissues, together with the clinical features of NS patients, predict key roles in a number of physiological processes. It is likely that LEKTI plays a role in terminal epidermal differentiation and/or corneocyte desquamation (13), as suggested by its restricted expression in the granular layer of the epidermis, and impaired keratinization and cornification in NS. Among possible targets are the stratum corneum trypsinand chymotrypsin-like enzymes (SCTE and SCCE, respectively) (33), whose defective inhibition by LEKTI would result in over desquamation of corneocytes (13) . Other putative targets are trypsin-like serine proteases, including the membrane-type serine protease 1 (MT -SP1) (34) , which could mediate inhibition of keratinocyte differentiation through activation of PAR-2 (protease-activated receptor-2) at the keratinocyte surface (35) . The extent of atopic manifestations in NS, which are not seen in other congenital ichthyoses, also predicts a role for LEKTI as a downregulator of inflammatory and/or immune allergic responses (36) . Two recent independent studies reporting association between SPINK5 missense variants and atopic dermatitis (37, 38) further support this assumption. Among the serine proteases secreted during the inflammation process, the trypsin -like mast cell tryptase is a major mediator of numerous allergic and inflammatory conditions (39) . Induction of inflammatory cytokines cell secretion including the major house dust-mite and pollen (45) . It is thus possible that lack of inhibition of some of these activities by LEKTI may also contribute to the allergen hyper-responsiveness associated with NS pathology. Despite absence of significant immune function abnormalities in NS patients (6), the strong and localised expression of LEKTI in thymic Hassall's corpuscles suggests that the protein could be involved in the regulation of T cell maturation. Although the functional significance of Hassall's corpuscles remains to be determined, recent findings suggest that these are involved both in maturation of developing thymocytes (46) , and activation and tolerisation of mature T cells (47) . For its specific expression in Hassall's corpuscles (48), the trypsin -like kallikrein 6 (KLK6) serine protease represents a potential target of LEKTI inhibitory activity. LEKTI expression in differentiated and keratinizing areas of the hair follicle (Fig. 7A-C ) and sebaceous glands (Fig. 7D) suggests a possible role in growth and differentiation of pilosebaceous units. This assumption is further supported by the specific hair shaft abnormality, trichorrhexis invaginata (TI), and slow growing hair feature observed in NS patients. Interestingly, LEKTI co-localises with SCCE and SCTE in hair (inner root sheath, and innermost layers of the outer root sheath in the uppermost follicle) and sebaceous (duct) follicles (33, 49) . This observation raises the possibility that, like in epidermis, LEKTI may regulate the activity of these serine proteases in pilosebaceous follicles. Lack of LEKTI expression in NS hair may lead to impaired keratinization of structures of the hair shaft, which could account for softening and collapse of its distal part into its proximal portion when driven upward by the growing force, resulting in the formation of TI bamboo nodes (50) . Reports of morphological abnormalities in the keratogenous zone of the hair cortex, and unkeratinised hair cuticle cells in TI (50) also correlate with the predicted lack of LEKTI expression in this location. The predisposition of NS patients to cutaneous infections of bacterial and viral origins could be attributed to the severe skin permeability barrier dysfunction, facilitating invasion by microorganisms. However, their persistent/recurrent character, unique to NS among ichthyoses (6), suggests additional loss of an important host-defense mechanism in the skin. Anti-microbial and anti-viral activities have been described for a number of serine protease inhibitors (51), including the antileukoprotease (ALP) (52) , and β defensins secreted by keratinocytes (53) . It is thus possible that LEKTI-derived bioactive peptides/polypeptides share similar activities as part of the innate immune response in the skin. Given its tissue distribution, a role for LEKTI in the general anti-microbial protection of mucous epithelia is also anticipated. Surprisingly, particular organs relevant to NS pathology such as lung, kidney and digestive tract were negative for LEKTI expression in normal individuals (Table 1 ). This suggests that life-threatening complications associated with NS, such as bronchopneumonia, malnutrition and metabolic disorders (6), are not primarily due to defective LEKTI function(s) in these organs, and may reflect a secondary effect resulting from failure to produce LEKTI in other tissues.
LEKTI full-length recombinant protein has recently been shown to inhibit the enzymatic activities of plasmin, trypsin, subtilisin A, cathepsin G and elastase (54) . This result supports the involvement of LEKTI in multiple biological pathways relevant to tissue homeostasis, inflammation and anti-microbial defense. Interestingly, the native D6 peptide shows a selective and more potent trypsin inhibition than the full-length recombinant protein, suggesting that the inhibitory potency of processed LEKTI domains against specific proteinases could be significantly higher than that of the precursor(s). These findings, together with our present data, further suggest that LEKTI proteolytic polypeptides represent bioactive forms, with different target specificities. The identification of the novel processed forms of LEKTI described in this study provides the basis for future functional and structural analysis of fragments with physiological relevance.
MATERIALS AND METHODS
Materials
All reagents, chemicals and antibodies were purchased from Sigma (Poole, UK) unless otherwise stated. Cell culture media were obtained from Invitrogen (Paisley, UK).
Tissue samples
A wide variety of normal human tissues, listed in Table 1 Committee approved the study and all patients gave informed consent.
Cloning of LEKTI full-length cDNA into pEF-DEST51 expression vector
LEKTI full-length cDNA (GenBank AJ228139) was generated by long-range PCR (Expand Long Template PCR System; Roche Molecular Biochemicals, E. Sussex, UK) using total cDNA from differentiated HK (obtained as described below) as a template. The PCR product was subcloned into pCRII-TOPO vector (TOPO TA Cloning Kit; Invitrogen) and transferred into the mammalian expression vector pEF-DEST51 using the Gateway technology, according to the manufacturer's instructions (Invitrogen). pEF-DEST51-LEKTI construct was fully sequenced using the Big Dye Terminator Sequencing Kit and an ABI377 automated sequencer (Applied Biosystem, Cheshire, UK) .
Cell culture and transfections
Normal and NS human primary keratinocytes (HK) were isolated from skin biopsies as previously described (55) . HK were expanded on a feeder layer of lethally irradiated 3T3-J2 mouse fibroblasts in keratinocyte-growth medium, following the method described by Rheinwald and G reen (56, 57) . For all experiments, HK were grown in the absence of 3T3 feeder layers in low calcium (<0.1 mM) keratinocyte serum-free medium (K-SFM) supplemented with epidermal growth factor (0.4 ng/ml) and bovine pituitary extract (25 µg/ml).
Cells were seeded in low calcium K-SFM at a density corresponding to 80% confluence in 60x15 mm tissue culture dishes or 8-well chamber slides (Nalge Nunc International, Naperville, IL, USA) for northern/western blot and immunofluorescence microscopy analysis, respectively.
Cell differentiation was induced for 24 hours in high calcium (1.2 mM) K-SFM. Further treatments with brefeldin A (BFA) and furin inhibitor I (Dec-RVKR-CMK; Calbiochem, Nottingham, UK) were performed for 6 hours at 10 µg/ml and 25-50 µM respectively, in high calcium K-SFM.
COS-1 cells were grown in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum, 100 U/l penicillin/streptomycin and 10 ng/ml L-glutamine. Cells were plated in 60x15mm tissue culture dishes at 70% confluence and transiently transfected with pEF-DEST51 or pEF-DEST51-LEKTI vectors (2.5 µg DNA), using FuGENE™ 6 Transfection Reagent according to the manufacturer's recommendations (Roche Molecular Biochemicals).
Transfected cells were maintained in culture for 48 hours before proceeding to western blot analysis.
RNA extraction, Reverse transcriptase-PCR, and northern blotting
Total RNA was isolated from normal and NS differentiated HK using Trizol (Invitrogen) according to the manufacturer's instructions. cDNA was generated from normal HK total RNA by reverse-transcription using the AMV reverse transcriptase (Roche Diagnostic Spa, Monza, Italy) and random hexamers. It was subsequently used as a template for the PCR amplification of a 273 bp cDNA product comprised within the 3' untranslated region of LEKTI cDNA sequence. PCR conditions were as described below with an annealing temperature of 59°C, and primers used were as follow s: 5'-CAGGAAGATTGTTGAAAGCCA-3' (sense, nucleotides 3239-3259) and 5'-ATTGAACAGGCAGTTGGACAG-3' (antisense, nucleotides 3491-3511).
The PCR product was radiolabeled and used as a probe for the northern blot analysis of 20 µg of total RNA extracts, following standard methods (58) . To assess uniformity of R NA loading and transfer, the membrane was further hybridized with a radiolabeled probe corresponding to the ubiquitously expressed gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH; GenBank NM002046). Quantification of the hybridization signals was performed by densitometric scanning using a GS-750 densitometer (Bio-Rad, Hercules, CA, USA).
Polyclonal LEKTI antibodies production
Rabbit polyclonal antibodies were raised against the recombinant N -terminal (D1-D6) and Cterminal (D13-D15) parts of LEKTI, and were termed α-N and α-C antibodies, respectively.
Construction of pGEX4T1-D1-D6 and pGEX3X-D13-D15 bacterial expression vectors-
fragments of LEKTI cDNA encoding the protein domains D1-D6 (nucleotides 52-1278) and D13-D15 (nucleotides 2483-3241) were generated by PCR using the following primers: Expression and purification of recombinant GST-fusion proteins-procedures were essentially performed as previously described (59) . Briefly, cell cultures were grown at 37°C in Luria Broth base (Invitrogen) medium containing 100 µg/ml ampicillin to an OD 600nm of 0.8. Protein expression was then induced by addition of IPTG to 0.1 mM, and cultures were grown overnight at room temperature. Cells were harvested, and lysed by sonication. Sonicates were clarified from insoluble material by centrifugation at 16,000 g, 4°C for 30 min. GST-D1-D6 (74.6 kDa) and GST-D13-D15 (55.6 kDa) were affinity purified using glutathione sepharose 4B beads, according to the manufacturer's recommendations (Amersham Pharmacia Biotech).
Immunisations-immunisations of rabbits with the recombinant antigens GST-D1-D6 and GST-D13-D15 were performed by Eurogentec Bel S.A (Herstal, Belgium) and Primm (Milan, Italy), respectively.
Serum purification-α-C and α-N crude antisera were purified by affinity chromatography for the respective antigens, using NHS-activated Sepharose® 4 Fast Flow (Amersham Pharmacia Biotech) and the AminoLink Plus Immobilisation Trial purification procedure (Pierce, Rockford, IL, USA), respectively, following manufacturers' instructions.
Monoclonal LEKTI antibody production
BALB/c mice were immunised four times with 50 µg of recombinant GST-D1-D6 at two-week intervals, once subcutaneously and thrice intraperitoneally, in association with complete (first injection), incomplete (second and third injections) and without (fourth injection) Freund's adjuvant (Calbiochem, La Jolla, CA). Three days after the fourth immunisation, fusion of the spleen cells with the non-Ig-producing myeloma cell line X63 Ag8 653 was performed using standard techniques (60) . When hybridoma growth could be detected, supernatants were tested for antibody-binding activity using an enzyme linked immunosorbent assay (ELISA). Of the 295 clones generated, one was found to secrete anti -D1-D6 antibody, as determined by ELISA and immunohistochemistry (see below). The selected hybridoma was cloned by limiting dilution. Isotope characterization showed that the anti-D1-D6 monoclonal antibody belongs to an IgG1 subclass.
Immunofluorescence microscopy
Cells were fixed in ice-cold methanol for 30 min and processed for immunofluorescence analysis, as previously described (61) . The primary antibodies used were LEKTI polyclonal α-N (11 µg/ml) and α-C (4 µg/ml) antibodies, the corresponding rabbit pre-immune sera used at the same dilutions, and the monoclonal anti-calreticulin antibody (Calbiochem). Secondary antibodies were goat anti-rabbit conjugated to FITC and sheep anti-mouse conjugated to TRITC. For competition experiments, α-N and α-C antibodies were pre-incubated for 1 hour at room temperature with 2.5-fold excess (weight) of the respective recombinant antigens GST-D1-D6 and GST-D13-D15, prior to immunodetection. Cells were mounted in Vectorshield in the presence or absence of propidium iodide (Vector laboratories, Peterborough, UK), and examined under a Nikon Optiphot with a 60X oil objective. Images were captured using an MRC 1024 confocal laser microscope and collected using Lasersharp software (Bio-Rad).
Western blotting
Cells were lysed in a suitable volume of ice-cold lysis buffer ( Blots were immunostained following standard protocols (60) . First antibodies were LEKTI polyclonal α-N (1.9 µg/ml), α-C (1.2 µg/ml), and monoclonal α-N (1 µg/ml) antibodies, and the corresponding rabbit pre-immune sera used at the same dilutions. Secondary antibodies were donkey anti-rabbit or sheep anti-mouse antibodies conjugated to horseradish peroxidase (Amersham Pharmacia Biotech). Proteins were visualized using the ECL detection system according to the manufacturer's instructions (Amersham Pharmacia Biotech). Competition experiments were performed as described above using 2.5-fold excess (weight) of the recombinant antigens. To verify equal sample loading, membranes were stripped following Amersham's ECL detection system instructions, and reprobed using the anti -tubulin monoclonal antibody. PNGase F (New England Biolabs, Hitchin, UK) and human recombinant furin sample treatments were performed for one hour at 37°C and 30°C, respectively, according to the manufacturer's instructions.
Immunohistochemistry
LEKTI α-N polyclonal and monoclonal antibodies worked on paraffin sections only, whilst α-C polyclonal antibodies also worked on frozen sections. These antibodies were used on a large panel of normal human tissue samples (Table 1) , as well as on skin biopsies from patients affected with NS or other skin disorders (Table 2) . Tissue samples were fixed in 10% neutral buffered formalin. 4 µm sections were prepared from paraffin -wax embedded tissues and their reactivity with LEKTI antibodies was investigated by immunohistochemistry. Prior to immunodetection, specimens were deparaffinized, rehydrated and processed as described elsewhere (62) . Antigen retrieval of dewaxed sections was performed by heat-treatment for 40 min using a water bath at 95°C in 10 mM citrate buffer pH 6.0 supplemented with 1% Tween 20, or using the Target Retrieval Solution (Dako, Trappes, France). Sections were immunostained for 30 min at room temperature with polyclonal α-N (11 µg/ml) or α-C (4 µg/ml) antibodies diluted in PBS containing 0.3% BSA, or with the undiluted α-N monoclonal antibody (5 µg/ml). Tissue sections were incubated with the streptavidin-biotin -peroxidase complex (ABC method) using the StrepABComplex/HRP Duet (mouse/rabbit) kit (Dako).
Extensive washing with PBS containing 0.3% BSA was performed between each step.
Labelling was revealed using diaminobenzidine tetrahydrochloride and hydrogen peroxide, and nuclei were counterstained with hematoxylin. Negative controls were included for each sample by omitting the primary antibody. The labelling specificity was verified using the corresponding pre-immune sera at the same concentrations and by competition experiments, as described above, using 10-fold excess (weight) of the recombinant antigens. 
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